These results suggested that high expression of ARHGAP11A elevated mortality risk for ccRCC patients, and the mortality rate was 1.949 times higher than those with low expression of ARHGAP11A. This evidence concerns the gene ARHGAP11A and nonpapillary renal cell carcinoma.